News
GRI
0.8500
+2.61%
0.0216
Weekly Report: what happened at GRI last week (1223-1227)?
Weekly Report · 12/30/2024 10:56
GRI Bio announces issuance of decision to grant for European patent on GRI-0803
TipRanks · 12/23/2024 14:10
GRI BIO: EUROPEAN PATENT OFFICE ISSUED DECISION TO GRANT NOTICE FOR PATENT COVERING GRI-0803 & ITS LIBRARY OF 500+ PROPRIETARY COMPOUNDS
Reuters · 12/23/2024 14:07
GRI Bio Secures European Patent Approval For GRI-0803 And 500+ Proprietary Compounds
Benzinga · 12/23/2024 14:02
Weekly Report: what happened at GRI last week (1216-1220)?
Weekly Report · 12/23/2024 11:02
Weekly Report: what happened at GRI last week (1209-1213)?
Weekly Report · 12/16/2024 11:03
GRI Bio Initiated at Buy by HC Wainwright & Co.
Dow Jones · 12/09/2024 11:31
GRI Bio Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow Jones · 12/09/2024 11:31
HC Wainwright & Co. Initiates Coverage On GRI Bio with Buy Rating, Announces Price Target of $10
Benzinga · 12/09/2024 11:20
GRI Bio initiated with a Buy at H.C. Wainwright
TipRanks · 12/09/2024 11:11
GRI BIO, INC. <GRI.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING
Reuters · 12/09/2024 11:03
Weekly Report: what happened at GRI last week (1202-1206)?
Weekly Report · 12/09/2024 11:02
U.S. RESEARCH ROUNDUP-Cheniere Energy, Redwood Trust, Verisign
Reuters · 12/09/2024 07:01
GRI Bio to Participate in the Virtual Investor Closing Bell Series
Barchart · 12/06/2024 07:35
GRI Bio Price Target Raised to $13.00/Share From $12.00 by Ascendiant Capital
Dow Jones · 12/05/2024 09:45
GRI Bio Is Maintained at Buy by Ascendiant Capital
Dow Jones · 12/05/2024 09:45
Ascendiant Capital Maintains Buy on GRI Bio, Raises Price Target to $13
Benzinga · 12/05/2024 09:35
Weekly Report: what happened at GRI last week (1125-1129)?
Weekly Report · 12/02/2024 11:02
Weekly Report: what happened at GRI last week (1118-1122)?
Weekly Report · 11/25/2024 10:55
GRI Bio Presents Positive Preclinical Data on GRI-0621 for Treating Pulmonary Fibrosis at AFDD Summit
Barchart · 11/21/2024 17:52
More
Webull provides a variety of real-time GRI stock news. You can receive the latest news about GRI Bio through multiple platforms. This information may help you make smarter investment decisions.
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).